These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1638 related items for PubMed ID: 14564315

  • 1. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 2. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M.
    Drugs; 2002 Oct; 62(12):1755-70. PubMed ID: 12149045
    [Abstract] [Full Text] [Related]

  • 3. Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Vernon SM.
    Cardiol Clin; 2001 May; 19(2):235-52, vi. PubMed ID: 11407108
    [Abstract] [Full Text] [Related]

  • 4. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 5. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 19; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 6. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 7. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ.
    J Invasive Cardiol; 2004 Feb 27; 16(2):46-51. PubMed ID: 14760188
    [Abstract] [Full Text] [Related]

  • 8. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 27; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW.
    J Am Coll Cardiol; 2008 Sep 02; 52(10):807-14. PubMed ID: 18755342
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators.
    JAMA; 2004 Jul 07; 292(1):55-64. PubMed ID: 15238591
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 07; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
    Ferguson JJ.
    J Invasive Cardiol; 2000 Dec 07; 12 Suppl E():E10-3;discussion E25-8. PubMed ID: 11156723
    [Abstract] [Full Text] [Related]

  • 17. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.
    Herz; 2003 Aug 07; 28(5):393-403. PubMed ID: 12928738
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2004 Aug 11; 292(6):696-703. PubMed ID: 15304466
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.